Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th Ready to Announce with Confidence?
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.
Planet MicroCap Las Vegas 2026
Dates: June 16-18, 2026
Location: Bellagio Hotel & Casino, Las Vegas, NV
Booth: #410
Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M. PT
Presentation Location: Track 7 - Donatello 3
Webcast: Viewable here
The Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedule a meeting with the Envoy Medical management team, please contact KCSA Strategic Communications at Envoy@kcsa.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300016
Source: Envoy Medical, Inc.
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Envoy Medical, Inc. or all companies in the Healthcare and Hospitals, Biotechnology industry.
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
2026-06-04 8:30 AM EDT
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
2026-05-20 8:30 AM EDT
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
2026-05-11 8:00 AM EDT
Feb 27, 2026
An advisor enters a ticker into a brokerage dashboard. A retail investor searches a fund on Yahoo Finance. An institutional analyst checks a terminal feed before a client meeting. In that moment, they are not simply looking for a price quote. They are looking for context. And increasingly, what they see is silence. The global ETF market now exceeds $20 trillion in assets under management. At the end of November 2025, the industry included more than 15,600 products and over 30,000 ...
Economy, Business and Finance
Biotechnology
Chemicals
Health
Hospital and Clinic
Healthcare and Hospitals
Biotechnology